|
1
|
Matsuda A, Matsuda T, Shibata A, Katanoda
K, Sobue T and Nishimoto H; Japan Cancer Surveillance Research
Group, : Cancer incidence and incidence rates in Japan in 2008: A
study of 25 population-based cancer registries for the monitoring
of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol.
44:388–396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beavon IR: The E-cadherin-catenin complex
in tumour metastasis: Structure, function and reglation. Eur J
Cancer. 36:1607–1620. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ngan CY, Yamamoto H, Seshimo I, Ezumi K,
Terayama M, Hemmi H, Takemasa I, Ikeda M, Sekimoto M and Monden M:
A Multivariate analysis of adhesion molecules expression in
assessment of colorectal cancer. J Surg Oncol. 95:652–662. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lugli A, Lezzi G, Hostettler I, Murano MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugino T, Gorham H, Yoshida K, Bolodeoku
J, Nargund V, Cranston D, Goodison S and Tarin D: Progressive loss
of CD44 gene expression in invasive bladder cancer. Am J Pathol.
149:873–882. 1996.PubMed/NCBI
|
|
9
|
Bhangu A, Wood G, Beown G, Darzi A, Tekkis
P and Goldin R: The role of epithelial mesenchymeal transition and
resistance to neoadjuvant therapy in localy advanced rectal cancer.
Colorectal Dis. 16:O133–O143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dorudi S, Sheffield JP, Pouulsom R,
Northover JM and Hart IR: E-cadherin expression in colorectal
cancer: An immunetochemical and in situ hybridization study. Am J
Pathol. 142:981–986. 1993.PubMed/NCBI
|
|
11
|
Ghadimi BM, Behrens J, Hoffman I, Haensch
W, Birchmeier W and Schlag PM: Immunohistological analysis of
E-cadherin, alpha-, beta- and gamma-catenin expression in
colorectal cancer: Implications for cell adhesion and signaling.
Eur J Cancer. 35:60–65. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121:727–735.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shintani Y, Maeda M, Chaika N, Johnson KR
and Wheelock MJ: Collagen I promotes epithelial-to-mesenchymal
transition in lung cancer cells via transforming growth-factor
signaling. Am J Respir Cell Mol Biol. 38:95–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suyama K, Shapiro I, Guttman M and Hazan
RB: A signaling pathway leading to metastasis is controlled by
N-cadherin and the FGF receptor. Cancer Cell. 2:301–314. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanwar SS, Yu Y, Nautiyal J, Patel BB and
Majumdar AP: The Wnt/beta-catenin pathway regulates growth and
maintenance of colonospheres. Mol Cancer. 9:2122010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyake K, Underhill CB, Lesley J and
Kincade PW: Hyaluronate can function as a cell adhesion molecule
and CD44 participates in hyaluronate recognition. J Exp Ned.
172:69–75. 1990. View Article : Google Scholar
|
|
17
|
Aruffo A, Stamenkovic I, Melnick M,
Underhill CB and Seed B: CD44 is the principal cell surface
receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dougherty GJ, Lansdorp PM, Cooper DL and
Humphries RK: Molecular cloning of CD44R1 and CD44R2, two novel
isoforms of the human CD44 lymphocyte ‘homing’ receptor expressed
by hemopoietic cells. J Exp Med. 174:1–5. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goldstein LA, Zhou DF, Picker LJ, Minty
CN, Bargatze RF, Ding JF and Butcher EC: A human lymphocyte homin
receptor, the hermes antigen, is related to cartel proteoglycan
core anf link proteins. Cell. 56:1063–1072. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stamenkovic I, Amiot M, Pesando JM and
Seed B: A lymphocyte molecule implicated in lymph node homing is a
member of the cartel link protein family. Cell. 56:1057–1062. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marhaba R and Zöller M: CD44 and in cancer
progression: Adhesion, migration and growth regulation. J Mol
Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sugano K, Maeda K, Ohtani H, Nagahara H,
Shibutani M and Hirakawa K: Expression of xCT as a predictor of
disease recurrence in patients with colorectal cancer. Anticancer
Res. 35:677–682. 2015.PubMed/NCBI
|
|
23
|
Al-Maghrabi J, Gomaa W, Buhmeida A,
Al-Qahtani M and Al-Ahwal M: Decreased immunoexpression of standard
form of CD44 is an independent favourable predictor of nodal
metastasis in colorectal carcinoma. Anticancer Res. 32:3455–3461.
2012.PubMed/NCBI
|
|
24
|
Jayne DG, Fook S, Loi C and Seow-Choen F:
Peritoneal carcinomatosis from colorectal cancer. Br J Surg.
89:1545–1550. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi H, Kotake K and Sugihara K:
Prognostic scoring system for stage IV colorectal cancer: Is the
AJCC sub-classification of stage IV colorectal cancer appropriate?
Int J Clin Oncol. 18:696–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barker N and Clevers H: Tumor environment:
A potent driving force in colorectal cancer? Trends Mol Med.
7:535–537. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bates RC: Colorectal cancer progression:
Integrin alphavbeta6 and the epithelial-mesenchymal transition
(EMT). Cell Cycle. 4:1350–1352. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brabletz T, Hlubek F, Spaderna S,
Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and
metastasis in colorectal cancer: Epithelial-mesenchymal transition,
mesenchymal-epithelial transition, stem cells and beta-catenin.
Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arias AM: Epithelial mesenchymal
interactions in cancer and development. Cell. 105:425–431. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal state: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wijnhoven BP, Dinjens WN and Pignatelli M:
E-cadherin-catenin cell-cell adhesion complex and human cancer. Br
J Surg. 87:992–1005. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zlobec I, Lugli A, Baker K, Roth S, Minoo
P, Hayashi S, Terracciano L and Jass JR: Role of APAF-1, E-cadherin
and peritumoral lymphocytic infiltration in tumour budding in
colorectal cancer. J Pathol. 212:260–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He X, Chen Z, Jia M and Zhao X:
Downregulated E-cadherin expression indicates worse prognosis in
Asian patients with colorectal cancer: Evidence from meta-analysis.
PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sleeman J, Kondo K, Moll J, Ponta H and
Herrlich P: Variant exon v6 and v7 together expand the repertoire
of glycolsaminoglycans bound by CD44. J Biol Chem. 272:31837–31844.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mulder JW, Kruyt PM, Sewnath M, Oosting J,
Seldenrijk CA, Weidema WF, Offerhaus GJ and Pals ST: Colorectal
cancer prognosis and expression of exon-v6-containing CD44
proteins. Lancet. 344:1470–1472. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morrin M and Delaney PV: CD44v6 is not
relevant in colorectal tumour progression. Int J Colorectal Dis.
17:30–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stanczak A, Stec R, Bodnar L, Olszewski W,
Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M and
Lamparska-Przybysz M: Prognostic significance of Wnt-1, β-catenin
and E-cadherin expression in advanced colorectal carcinoma. Pathol
Oncol Res. 17:955–963. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ilyas M, Novelli M, Wilkinson K, Tomlinson
IP, Abbasi AM, Forbes A and Talbot IC: Tumour recurrence is
associated with Jass grouping but not with differences in
E-cadherin expression in moderately differentiated Dukes' B
colorectal cancers. J Clin Pathol. 50:218–222. 1997. View Article : Google Scholar : PubMed/NCBI
|
